Video: Black Doctor Wears Scrubs to Protect Himself
WebMD Chief Medical Officer John Whyte talks with Dr Arturo Holmes II about why he wears his physician scrubs out in public. Watch... Read More
Phase 3 Results From the MEAL Study: Does a High-Veggie Diet a Day Keep Prostate Cancer Progression at Bay?
The MEAL study was a prospective, randomized [phase 3] clinical trial to assess whether or not a dietary intervention prevents... Read More
Prostate Cancer More Aggressive in Post-USPSTF Era
High-volume referral centers throughout the United States are seeing a consistent decrease in low-grade prostate cancer and an absolute increase... Read More
Aggressive Prostate Cancer Type Is ‘Fairly Prevalent’
Many clinicians who treat men with prostate cancer may be unfamiliar with the term “treatment-emergent small-cell neuroendocrine prostate cancer” (t-SCNC).... Read More
$200K Saved With First-Line Docetaxel for Prostate Cancer
Two systemic drugs for the treatment of newly diagnosed metastatic prostate cancer, docetaxel (Taxotere, Pfizer) and abiraterone acetate (Zytiga, Janssen),... Read More
ASCO President Talks of ‘New Understanding’ After Own Cancer
Addressing a packed hall at the American Society of Clinical Oncology (ASCO) 2018 annual meeting, the president of ASCO drew... Read More
Prostate Cancer on the Rise; Time to Revisit Guidelines?
In 2012, the US Preventive Services Task Force recommended against routine prostate cancer screening of asymptomatic men to detect early... Read More
Can Diet Influence Prostate Cancer Progression?
Can diet modification reduce prostate cancer progression in men undergoing active surveillance? An ongoing study is slated to answer just... Read More
In a First, US Insurer Covers HIFU for Prostate Cancer
The announcement that patients in the United States who have localized radio-recurrent prostate cancer are potentially eligible for insurance coverage... Read More
Docetaxel for Prostate Cancer: ‘Win-Win-Win’
Adding the chemotherapy docetaxel to standard hormone therapy for both metastatic and nonmetastatic prostate cancer is a win-win-win because it... Read More